{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-028111","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2026-08-17T12:00:30+00:00","discovered_at":"2026-08-17T12:05:03.200485+00:00","generated_at":"2026-08-17T12:06:03.757171+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NRx Q2 2026: net loss $18M, cash $26.7M; FDA ketamine ANDA only needs attestation","bullets":["FDA review of ANDA for preservative-free ketamine found no drug-related major deficiencies; only manufacturer's attestation submitted, aiming for 2026 approval.","Closed underwritten public offering for gross proceeds of $22.3M; cash at June 30, 2026 was $26.7M vs $7.8M at Dec 31, 2025.","Selected by DARPA as prime contractor for SPARC-TMS trial of NRX-101 with robotic TMS; non-dilutive funding >$11.5M.","Appointed Glenn Tyson as first Chief Commercial Officer; initiated commercial scale manufacturing of 5M ketamine doses.","Net loss for six months ended June 30, 2026 was $18.0M vs $23.1M in 2025; net operating loss $11.3M vs $7.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-028111","json":"https://secwatch.observer/filing/0001437749-26-028111.json","markdown":"https://secwatch.observer/filing/0001437749-26-028111.md","text":"https://secwatch.observer/filing/0001437749-26-028111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774926028111/0001437749-26-028111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774926028111/nrxp20260817_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-17T12:06:03.757171+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}